MYRIAD GENETICS INC

For the period ended Jun 30, 2026. Filed Jul 31, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Jul 31, 2026

MYGN$5.67-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations for theand(unaudited)

Condensed Consolidated Statements of Operations (unaudited)

(in millions, except per share amounts)

	Three months endedJune 30,		Six months endedJune 30,
	2026	2025	2026	2025
Revenue	$190.7	$213.1	$391.1	$409.0
Cost of revenue	63.7	61.3	126.5	123.0
Gross profit	127.0	151.8	264.6	286.0
Costs and expenses:
Research and development expense	25.0	25.6	52.1	53.1
Sales and marketing expense	83.1	71.9	156.7	141.1
General and administrative expense	57.8	66.8	120.0	133.3
Goodwill and long-lived asset impairment charges	—	316.7	5.4	316.7
Total operating expenses	165.9	481.0	334.2	644.2
Operating loss	(38.9)	(329.2)	(69.6)	(358.2)
Other income (expense):
Interest income	0.4	0.2	1.1	0.5
Interest expense	(4.1)	(1.5)	(8.2)	(2.3)
Other	—	(0.1)	—	—
Total other expense, net	(3.7)	(1.4)	(7.1)	(1.8)
Loss before income tax	(42.6)	(330.6)	(76.7)	(360.0)
Income tax expense (benefit)	0.6	(0.1)	0.6	(29.4)
Net loss	$(43.2)	$(330.5)	$(77.3)	$(330.6)
Net loss per share:
Basic and diluted	$(0.46)	$(3.57)	$(0.82)	$(3.59)
Weighted average shares outstanding:
Basic and diluted	94.8	92.5	94.2	92.0

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.